BioMark Contributes Additional Scientific Publication

Vancouver, British Columbia – (March 14th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed journal Future Science OA.

 

Rashid Ahmed, President and CEO, says, “This is our follow up publication and we would like to acknowledge the contributions made by a dedicated team of clinicians, scientists and researchers. This publication provides further scientific validation and evidence that one of our technology platforms (SSAT1 assay) has important clinical applications in the cancer diagnostic space. We believe that the SSAT1 assay platform is robust and can be leveraged to detect other cancer types. Potential utility of the assay includes being used as a surveillance test in populations at high risk for developing cancer and for monitoring patients after surgical or chemo/radiation therapy to detect not only the response of the tumor to the intervention, but also the possibility to detect the proliferation of new cancer cells.”

 

“BioMark is looking forward to publishing additional peer reviewed papers and present abstracts or posters in the near term on significant discoveries that it has invested resources over the past few years.” says Rashid.

 

The paper is available through open access at https://www.future-science.com/doi/full/10.4155/fsoa-2018-0106. BioMark encourages subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in biotechnology and medicine.

 

About Future Science OA

Future Science and Newlands Press, imprints of Future Science Group, focus on applied science and intellectual property issues in R&D. The journals and eBooks take readers through the pharmaceutical R&D pipeline – from drug discovery, delivery, pharmacokinetics and analytical techniques, through to commentary and analysis on patent and IP issues. The flagship gold open access journal, Future Science OA, also embraces the importance of publishing all good-quality research, and covers all areas of biotechnology and medicine, as well as topics in biological, life and physical sciences that are of relevance to human health.

 

Future Science Journals

Future Science journals provide research professionals worldwide with a unique source of objective cutting-edge information on the most exciting emerging trends in their field of endeavour.

Access to publications is possible via print and online subscriptions or via pay-per-view purchase via the website (for more information, see Subscriptions and Pricing).

Contact:

Laura Dormer, Editorial Director

Future Science Group,
Unitec House,
2 Albert Place,
London,
N3 1QB, UK

 

Press Release – BioMark Contributes Additional Scientific Publication

Share this post:
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.